Insight, China's Pharmaceutical Industry

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that its Hector thoracic aortic multi‑branch stent...

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026

Hua Medicine (HKG: 2552) announced that the Department of Health in Hong Kong has approved HuaTangNing...

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Fineline Cube Mar 3, 2026

Lepu Medical Technology (SHE: 300003), a cardiovascular disease solutions provider, announced clinical approval from China’s National...

Company Drug

Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic

Fineline Cube Mar 3, 2026

Xellsmart, a Suzhou‑based stem‑cell startup, announced regulatory clearance from both China’s NMPA and the US...

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 3, 2026

Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib...

Digital Drug

ReviR Therapeutics Doses First Patient in RTX-117 Trial – China’s First “AI + RNA” Small Molecule Enters Clinic

Fineline Cube Mar 3, 2026

ReviR Therapeutics, a clinical‑stage biotech incubated by XtalPi (HKG: 2228), announced first subject dosing in a...

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026

Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed...

Company Drug

Roche’s Fenebrutinib Hits Phase III Endpoint in MS – BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care

Fineline Cube Mar 3, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the pivotal Phase III FENhance 1 study for fenebrutinib in relapsing...

Company Drug

Sanofi’s Rilzabrutinib Wins Japan Orphan Designation for IgG4‑RD – BTK Inhibitor Expands Rare Disease Portfolio

Fineline Cube Mar 3, 2026

Sanofi (NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan...

Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026

Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to...

Company Drug

CSPC Pharma’s SYHX2011G1 Wins FDA IND Approval – Instant‑Release Albumin‑Bound Paclitaxel for Metastatic Breast Cancer

Fineline Cube Mar 3, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026

Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to...

Company Drug

Gan & Lee’s AR PROTAC GLR2037 Wins NMPA Approval – First‑in‑Class Prostate Cancer Therapy Enters Clinic

Fineline Cube Mar 3, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

Hotgen Biotech Doses First Patient in AA001 Phase Ib – Anti‑Aβ mAb Targets Early Alzheimer’s Disease

Fineline Cube Mar 3, 2026

Hotgen Biotech Co., Ltd (SHA: 688068) announced first subject dosing in a Phase Ib clinical study...

Company

Novo Nordisk Invests €432M in Ireland Facility – Expands Oral GLP‑1 Manufacturing for Global Markets

Fineline Cube Mar 3, 2026

Novo Nordisk (NYSE: NVO) announced a €432 million (approx. DKK 3.2 billion) investment in its Monksland, Athlone, Ireland facility...

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026

Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib...

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026

Hangzhou HealZen Therapeutics Co., Ltd. announced that its self‑developed Category 1 innovative drug, HZ‑A‑018 capsules, has...

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Fineline Cube Mar 2, 2026

Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced that RBD7022 Injection, its independently developed siRNA...

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Fineline Cube Mar 2, 2026

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that GFH375, an oral KRAS G12D (ON/OFF) inhibitor, has...

Insight, China's Pharmaceutical Industry

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

ReviR Therapeutics Doses First Patient in RTX-117 Trial – China’s First “AI + RNA” Small Molecule Enters Clinic

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Roche’s Fenebrutinib Hits Phase III Endpoint in MS – BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care

Sanofi’s Rilzabrutinib Wins Japan Orphan Designation for IgG4‑RD – BTK Inhibitor Expands Rare Disease Portfolio

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

CSPC Pharma’s SYHX2011G1 Wins FDA IND Approval – Instant‑Release Albumin‑Bound Paclitaxel for Metastatic Breast Cancer

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Gan & Lee’s AR PROTAC GLR2037 Wins NMPA Approval – First‑in‑Class Prostate Cancer Therapy Enters Clinic

Hotgen Biotech Doses First Patient in AA001 Phase Ib – Anti‑Aβ mAb Targets Early Alzheimer’s Disease

Novo Nordisk Invests €432M in Ireland Facility – Expands Oral GLP‑1 Manufacturing for Global Markets

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

You Missed

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los